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Abstract
Two commonly prescribed treatments for opioid addiction are methadone and buprenorphine. 
While these drugs show some efficacy in treating opioid dependence, treatment response varies 
among individuals. It is likely that genetic factors play a role in determining treatment outcome. 
This study analyses the pharmacogenetic association of 6 polymorphisms in OPRD1, the gene 
encoding the delta-opioid receptor, on treatment outcome in 582 opioid addicted European 
Americans randomized to either methadone or buprenorphine/naloxone ((Suboxone®) over the 
course of a 24 week open-label clinical trial. Treatment outcome was assessed as the number of 
missed or opioid positive urine drug screens over the 24 weeks. In the total sample, no SNPs in 
OPRD1 were significantly associated with treatment outcome in either treatment arm. However, 
sex-specific analyses revealed 2 intronic SNPs (rs581111 and rs529520) that predicted treatment 
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outcome in females treated with buprenorphine. Females with the AA or AG genotypes at 
rs581111 had significantly worse outcomes than those with the GG genotype when treated with 
buprenorphine (p=0.03, RR=1.67, 95% C.I.[1.06-2.1]). For rs529520, females with the AA 
genotype had a significantly worse outcome than those with the CC genotype when (p=0.006, 
RR=2.15, 95%C.I.[1.3-2.29]). No significant associations were detected in males. These findings 
suggest that rs581111 and rs52920 may be useful when considering treatment options for female 
opioid addicts, however confirmation in an independent sample is warranted.
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Introduction
In 2010, 1.17 million people in the United States received treatment for addiction to opioids 
or illicit use of opioids. The majority of these individuals were abusing or dependent upon 
prescription opioid analgesics (1). While the number of individuals receiving treatment for 
alcohol and illicit drug abuse has remained relatively stable since 2002, the number of those 
receiving treatment for the abuse of opioid analgesics has more than doubled (National 
Survey on Drug Use and Health, 2010). The two most commonly prescribed FDA-approved 
treatments for opioid addiction are methadone and buprenorphine, which act by binding to 
opioid receptors. Methadone acts as an agonist at the μ-opioid receptor (MOR) (2), whereas 
buprenorphine is a MOR partial agonist and a κ-opioid receptor (KOR) antagonist (Leander, 
1987). Opioid signaling via the δ-opioid receptor (DOR) has also been observed in mice 
chronically treated with methadone (3) and buprenorphine has a high affinity for DOR (4).
The gene encoding DOR (OPRD1) has previously been associated with the risk for opioid 
addiction. A study of German heroin addicts found a synonymous SNP in OPRD1 to be 
associated with addiction (5), and a study analyzing OPRD1 in European Americans found a 
non-synonymous SNP to increase risk for opioid and general substance addiction (6). In a 
large case-control study of Australian heroin addicts, intronic OPRD1 SNPs, including the 
SNP rs2236857, were found to associate with addiction (7). A previous study of severe 
heroin addiction also found rs2236857 to be nominally associated in European Americans 
(8). Negative findings, that fail to associate OPRD1 polymorphisms with heroin addiction 
have also been reported (9-11).
Methadone and buprenorphine have substantial efficacy for the treatment of opioid addiction 
(12); however, a subset of patients relapse, are non-compliant with treatment protocols, and 
continue to use illicit opioids (12-18). There are a number of factors that influence treatment 
outcome, including a prior history of drug abuse, medication dosage, polydrug abuse, and 
ethnic differences (19-22). Patient sex is also known to influence treatment outcome and 
significant sex differences are reported in the progression from opioid abuse to seeking 
treatment, the subsequent use of health services, drug metabolism, and the clinical profiles 
of opioid abusers (23-26).
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Sexual dimorphism in the response to opioids is reported in both animals and humans (27). 
Morphine may be more potent in women (28); however, due to a slower onset of action 
women require more morphine for analgesic effects (29, 30). Furthermore, women report 
greater analgesia from KOR agonists compared to males (31-33). Female rats have increased 
levels of KOR/MOR heterodimers in the spinal cord (34), which affects morphine 
antinociception, and this has been shown to be dependent on levels of spinal estrogen (35).
Genetic factors are also associated with treatment outcome for opioid addiction (36, 37). A 
recent pharmacogenetic study of methadone and buprenorphine treatment for opioid 
addiction analyzed whether polymorphisms in OPRD1 would predict the number of opioid 
positive urine drug screens in individuals over the course of a 24 week open randomized 
trial (36). In this study a T/C intronic SNP, rs678849, was found to predict treatment 
outcome for individuals of African American descent. African Americans carrying a T allele 
at rs678849 were found to have fewer opioid positive urine samples when treated with 
methadone; however, individuals with the C/C genotype had better outcomes when treated 
with buprenorphine.
Despite the growing evidence for sex differences in the response to opioids, little research 
has been done to identify sex-specific pharmacogenetic effects in treatment for opioid 
dependence. A recently published paper from our group found SNPs in OPRD1 to be 
associated with the response to methadone and buprenorphine in African American opioid 
addicts, however, they found no association in European Americans (36). Using the same 
sample of European Americans, the present study analyzed the association of SNPs in 
OPRD1 in males and females separately, in order to identify sex-specific pharmacogenetic 
effects. The sample utilized was part of an open-label randomized clinical trial designed to 
assess the effects of methadone and buprenorphine on liver function, which also collected 
genetic material and data on treatment response (38).
Materials and Methods
Participants and Procedures
The current data were obtained from a National Drug Abuse Treatment Clinical Trials 
Network (CTN) study. The main outcome measures and study design for this clinical trial 
have been described in detail previously (38). In summary, individuals seeking treatment for 
opioid addiction were recruited at federally licensed opioid treatment programs in the United 
States between May 2006 and October 2009. Institutional review boards at participating 
sites approved the study, and the NIDA Clinical Trials Network Data Safety and Monitoring 
Board provided oversight. All patients were at least 18 years of age and met DSM-IV-TR 
criteria for opioid dependence. Exclusion criteria for the trial included: cardiomyopathy, 
liver disease, acute psychosis, blood levels of alanine amino transferase or aspartate amino 
transferase greater than 5 times the maximum normal level, or poor venous access. Patients 
were randomly assigned to 24 weeks of open-label buprenorphine/naloxone ((Suboxone®) 
or methadone treatment. Patients were defined as European American if they primarily self-
identified as ‘white’ in the study. This also includes a number of patients who identified 
‘Latino’ as a secondary identifier (N males=22, N females= 13).
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A flexible dosing approach was used, with a wide range allowed in both induction dosing 
and subsequent maintenance dosing. First day buprenorphine dose began at 2 to 8mg, which 
could be increased to 16mg in the case of persistent withdrawal. Buprenorphine could be 
further increased in subsequent days to a maximum dose of 32 mg; the mean maximum 
daily dose for the trial completers analyzed in this study was 24.5 ± 8.3 mg. The initial 
maximum dose of methadone was limited to 30 mg. For persistent withdrawal an additional 
dose was allowed up to a maximum total first day dose of 40 mg as stipulated by US statute. 
Methadone dose could be increased in subsequent days by 10 mg increments with no 
maximum. The mean maximum daily methadone dose for the trial completers analyzed in 
this study was 97.3 ± 45.0 mg. Patients came to the clinic daily for observed dosing except 
on Sundays and holidays or if local regulations permitted take-home medications. Weekly 
urine drug samples were taken and tested for opioids. Samples testing positive for 
methadone were counted as positive for individuals in the buprenorphine group, but not for 
individuals in the methadone group.
SNP selection and genotyping
SNPs with a minor allele frequency >10% were selected for genotyping using the Tagger 
algorithm implemented in the Haploview software package (http://www.broadinstitute.org/
haploview) (39). 6 SNPs were selected for genotyping (rs1042114, rs678849, rs10753331, 
rs529520, rs581111, and rs2234918) and these were found to tag 71% of SNPs in OPRD1 
with an r2 of 0.8 and a MAF cut-off of 10%, using the International HapMap project CEU 
population data (HapMap data release 28 phase II & III, August 2010, www.hapmap.org). 
Using a MAF cut-off of 5%, 62% of SNPs in OPRD1 were captured with an r2 of 0.8. 
rs2234918 was not genotyped in the HapMap population and is not included in the linkage 
disequilibrium (LD) calculation.
All SNPs were genotyped using Taqman® SNP Genotyping Assays (Applied Biosystems 
Inc. (ABI); Foster City, CA, USA) according to the standard Applied Biosystems protocol. 
Quality control was maintained by genotyping 10% duplicates, which were checked for 
genotype concordance across the population. The duplicate concordance rate was 100%.
Statistical Analysis
Initial comparisons of average outcome in males compared to females were analyzed by 
student’s t-test. For each SNP, deviation from Hardy-Weinberg was analyzed and all SNPs 
were in Hardy-Weinberg Equilibrium (p≥0.05). Gene × environment analyses were 
performed in the software package PLINK v1.07 (40) for the male and female groups 
separately, using the percentage of missed or opioid positive urine drug screens over the 24 
weeks as the phenotype. Treatment group (buprenorphine or methadone) was used as a 
covariate. P-values for the gene-environment analyses are reported as significant if they 
remain significant after correction for multiple testing using the (FDR) procedure with the 
cut-off for statistical significance after correction set to p≤0.05 (41). As rs581111 and 
rs529520 were found to be significant in the gene × environment analyses in females, the 
average percentage of missed or positive urine tests by rs581111 and rs529520 genotype 
were analyzed by one-way ANOVA with Tukey HSD post hoc analysis. Due to the low 
frequency of A homozygotes in the population for rs581111, the AA and AG genotypes 
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were combined for the ANOVA analysis. We used Generalized Estimating Equation (GEE) 
to investigate the associations of genotype and longitudinal urine drug screen outcomes from 
week 1 to week 24, adjusting for the effects of age, time (week), gender, and treatment 
group. GEE is a quasi-likelihood based method which produces population averaged 
estimates for longitudinal binary outcomes (42). As the GEE provides weighted estimates 
for missing data, the GEE was run with missing tests coded as positive, and again with 
missing tests coded as missing. We report our estimates as relative risks, and bootstrapped 
95% confidence intervals based on 1000 replicate samples. We analyzed urine drug screen 
outcomes for both treatment groups separately and for the entire sample as a whole, 
examining the main effects of treatment and rs581111 or rs529520 genotype, as well as the 
interaction effect of treatment × genotype.
Results
Demographics
DNA samples were available from 582 Europeans Americans who received either 
methadone or buprenorphine for the treatment of opioid dependence. The genetic analysis 
was restricted to European Americans in order to minimize the effects of genetic population 
sub-structure between different ethnicities. The number of males and females randomized to 
each group, the mean age, the average outcome for each treatment group and the average 
number of missed tests over 24 weeks are summarized in Table 1. The average percentage 
of positive urine tests over 24 weeks was not significantly different between males (51%) 
and females (43%, p=0.1) in the buprenorphine group or between males (43%) and females 
(45%, p=0.63) in the methadone group.
Gene × Environment Analysis
In order to determine if any of the OPRD1 genetic variants were associated with treatment 
outcome in either males or females, gene × environment analyses were run with the average 
number of missing or positive urine drug tests over the course of the 24 week trial used as 
the outcome variable. The results of these analyses are shown in Tables 2 and 3. No 
significant interactions were observed in males (Table 2); however, in females, rs581111 
(p=0.002) and rs529520 (p=0.005) were associated with the number of missing or positive 
urine drug tests (Table 3). Two additional SNPs, rs1042114 and rs10753331, were 
nominally associated with treatment outcome in females but these associations did not 
withstand correction for multiple testing. The GxE analysis was also run with the individuals 
who self-identified as ‘White/Latino’ removed. This was not found to affect the results, as 
rs529520 and rs581111 were still significantly associated with treatment outcome in females 
(data not shown).
Across the 24 weeks of the trial, female carriers of the rs581111 GG genotype had a fewer 
missing or positive opioid drug screens when treated with buprenorphine (31.5% ± 30.1%) 
compared to those patients with an AA or AG genotype (56.8% ±37.7%) (p<0.01). This 
association was not seen in the methadone treated group, as the percentage of missing or 
positive drug screens amongst the GG carriers (47.5% ±32.2%) compared to AA or AG 
carriers (40.4% ±32.0%) was not significantly different. No significant difference in 
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outcome was observed, in either the methadone or buprenorphine treatment groups based on 
rs529520 genotype.
Generalized Estimating Equation (GEE) analysis
GEE were used to calculate the effect of the gene × environment interaction when the 24 
weeks of urinalysis data were taken as repeated measures. A significant interaction between 
genotype at rs581111 and treatment group was observed (p=0.03, RR=1.67, 95%C.I.
[1.06-2.1]), confirming the original gene × environment finding. When treatment groups 
were analyzed separately, females with the AA or AG genotypes at rs581111 had 
significantly worse outcomes than those with the GG genotype when treated with 
buprenorphine (p=0.031, RR=1.72, 95%C.I.[1.25-1.97]) (Figure 1). However, no significant 
interaction was found in the methadone treated group (data not shown). For rs529520, a 
significant interaction of treatment and genotype was observed as females with the AA 
genotype had a worse outcome than those with the CC genotype when treated with 
buprenorphine (p=0.006, RR=2.15, 95% C.I.[1.3-2.29]) (Figure 2A). The number of missing 
or positive urine tests was not significantly different between the AC and AA genotypes 
(p=0.072, RR=1.51, 95% C.I.[0.99-2.06] (Figure 2B). When the buprenorphine treated 
cohort were analyzed separately the association of AA genotype with treatment outcome 
was still significant (p=0.05, RR=1.8, 95% C.I.[1.04-2.02]). No association was observed in 
the methadone treated individuals (data not shown).
The GEE was re-run with missing urine drug screens coded as ‘missing’ rather than 
‘positive’. Significant interactions of treatment and genotype remained for females treated 
with buprenorphine. For rs529520, carriers of the AA genotype did significantly worse than 
those with the CC genotype (p=0.025, RR=1.65, 95% C.I. [1.5-2.06]). For rs581111, the 
interaction of treatment and genotype was also significant, with carriers of the A allele 
having significantly worse outcomes than those with the GG genotype (p=0.009, RR=1.56, 
95% C.I. [1.41-1.78]).
Discussion
OPRD1 has been previously associated with heroin addiction and treatment outcome (5-8, 
36). The present study demonstrates that 2 SNPs located in intron 1, rs581111 and rs529520, 
predict treatment outcome in females treated with buprenorphine. Female opioid addicts 
with the GG genotype at rs581111 were found to have significantly better outcomes when 
treated with buprenorphine, compared to patients with the AG or AA genotype. Females 
with the CC genotype at rs529520 had significantly fewer missing or opioid positive drug 
screens over 24 weeks compared to those with the AA genotype. Levran et al. found 2 SNPs 
in intron 1 of OPRD1, rs2236857 and rs2236861, to be associated with heroin addiction and 
these SNPs are in LD (D’=1) with rs529520 and rs581111 respectively, however the r2 
between these SNPs in Europeans is modest (0.02-0.3). Furthermore, Nelson et al. 
demonstrated a haplotype of rs2236857 and rs581111 to be associated with heroin addiction. 
As we find rs581111 to also be associated with treatment outcome in females, these data 
lend further support to the importance of OPRD1 genotypes for opioid addiction.
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Sex differences that distinguish male and female opioid addicts have been previously 
reported (24, 43, 44). Female opioid addicts exhibit different drug abuse profiles and present 
with different medical and psychiatric problems compared to their male counterparts (23, 
25). While some of the differences in the clinical profiles of male and female opioid addicts 
may be societally or environmentally influenced, it is likely that some of this variance has a 
biological basis.
The opioid binding capacity of men and women in the brain has been shown to differ, as a 
study found women to have higher MOR binding as determined by positron emission 
tomography (PET) scanning (45). Furthermore, sex differences in the analgesic response to 
opioids have been reported for KOR agonists/antagonists, with KOR-acting analgesics 
producing greater analgesia in females compared to men (31-33). Furthermore, the 
pharmacokinetics of buprenorphine have been shown to differ between males and females 
and this is influenced by sex differences in body composition (26). Sexual dimorphism in 
DOR expression and function has also been observed. Female rats show an increase level of 
DOR associated with the plasma membrane in the nucleus accumbens core, following 
withdrawal from cocaine (46) and stress-induced analgesia was found to be decreased in 
female Oprm1-/-/Oprd1-/- mice when compared to males (47).
Given the inherent differences observed in the opioid system between males and females it 
is plausible that a pharmacogenetic effect involving OPRD1 polymorphisms and the 
response to buprenorphine would be sex-specific. Interestingly, a bioinformatic analysis of 
intron 1 of OPRD1 revealed a perfect estrogen response element (ERE) located just 77 base 
pairs away from rs581111. Furthermore, an ERE element is located in the promoter of 
OPRD1 (48), suggesting that OPRD1 gene expression may be regulated by estrogen. Levels 
of DOR are also affected by buprenorphine, as treatment in mice leads to an upregulation of 
DOR in the forebrain (49, 50). Furthermore, norbuprenorphine, a metabolite of 
buprenorphine, acts as a DOR agonist in vitro (51). These data, suggest that the OPRD1 
locus is worthy of further study when understanding treatment response to buprenorphine, 
specifically in females.
There are a number of limitations to this study. rs581111 and rs529520 are located 427 base 
pairs apart in intron 1 of OPRD1. From the genotyping data and statistical analysis alone, it 
is not possible to determine whether both of these SNPs are relevant for treatment outcome 
or whether the association at one SNP is affecting the result at the other. There is moderate 
LD between these 2 SNPs in the European population (D’=1, r2=0.46), and it is possible that 
these SNPs together tag another locus which is the causal variant for the phenotype observed 
in this study. Further work on the role of rs581111 and rs529520 in the context of OPRD1 
gene expression and DOR protein levels and re-sequencing of the OPRD1 locus is required 
to understand how these SNPs affect the response to treatment for opioid dependence in 
females. Another limitation to this study pertains to the handling of missing data. During the 
START trial, a higher rate of dropouts in the buprenorphine group was observed (38) 
compared to those treated with methadone. This may have influenced our analyses as our 
data show an association of genotype with treatment response in the buprenorphine arm of 
the trial. However, as the participants enrolled in this trial were opioid dependent, it is a 
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reasonable assumption that if they were not present to provide a urine sample and receive 
agonist replacement therapy, then it is likely that they were abusing opioids.
Finally, the number of women enrolled in the START trial is relatively low, with 104 
patients in the methadone arm of the trial and 81 in the buprenorphine arm. Therefore, in 
order to validate these findings, replication in an independent study is warranted. 
Confirming these associations will be an important finding in the field of opioid addiction 
treatment as these genotypes have the potential to determine the appropriate treatment 
regime for female opioid addicts.
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Figure 1. 
Longitudinal urinalysis data for females treated with buprenorphine for 24 weeks based on 
rs581111 genotype. Weekly urine drug screens were administered for the presence of 
opioids other than the one prescribed. The average percentage of missing or opioid positive 
urine tests during each week is provided for individuals with each genotype. Due to the low 
minor allele frequency of rs581111, A/A and A/G carriers are grouped together. Patients 
with the AA/AG genotypes were more likely to have opioid-positive urine drug 
screens(p=0.031, RR=1.72, 95% C.I.[1.25-1.97]). Error bars represent standard error of the 
mean.
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Figure 2. 
Longitudinal urinalysis data for females treated with buprenorphine for 24 weeks based on 
rs529520 genotype. Weekly urine drug screens were administered for the presence of 
opioids other than the one prescribed. The average percentage of missing or opioid positive 
urine tests during each week is provided for individuals with each genotype. A) Patients 
with the AA genotype were more likely to have missing or opioid-positive drug screens 
compared to patients with the CC genotype (p=0.025, RR=1.65). B) Patients with the AA 
genotype were not significantly different from patients with the AC genotype (p=0.072, 
RR=1.51, 95% C.I.[0.99-2.06]). Error bars represent standard error of the mean.
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Table 1
Demographic information and treatment outcomes for participants treated with methadone or buprenorphine 
for opioid dependence.
Treatment Group Methadone Methadone Buprenorphine Buprenorphine
Sex Female Male Female Male
Number 104 179 81 218
Mean Age ± SD 36.4 ± 10.1 35.2 ± 10.9 37.0 ± 11.5 35.6 ± 11.0
Mean % Positive Urinalysis ± SD 45.3 ± 32.7% 43.4 ± 31.6% 43.0 ± 36.2% 50.6 ± 35.7%
Mean % Missing Tests ± SD 12.1 ± 17.53% 13.01 ± 20.15% 23.1 ± 29.15% 25.73 ± 27.78%
SD = standard deviation.
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